About: Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials
Creator	Norman, Gail
source	Elsevier; Medline; PMC
abstract	Dramatically rising costs in drug development are in large part because of the high failure rates in clinical phase trials. The poor correlation of animal studies to human toxicity and efficacy have led many developers to question the value of requiring animal studies in determining which drugs should enter in-human trials. Part 1 of this 2-part series examined some of the data regarding the lack of concordance between animal toxicity studies and human trials, as well as some of the potential reasons behind it. This second part of the series focuses on some alternatives to animal trials (hereafter referred to as animal research) as well as current regulatory discussions and developments regarding such alternatives.
has issue date	2020-04-27(xsd:dateTime)
bibo:doi	10.1016/j.jacbts.2020.03.010
bibo:pmid	32363250
has license	no-cc
sha1sum (hex)	54ffc3dbb1b8e6c084d17a70dead90a3531cab30
schema:url	https://doi.org/10.1016/j.jacbts.2020.03.010
resource representing a document's title	Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Part 2: Potential Alternatives to the Use of Animals in Preclinical Trials
has PubMed Central identifier	PMC7185927
has PubMed identifier	32363250
schema:publication	JACC Basic Transl Sci
resource representing a document's body	covid:54ffc3dbb1b8e6c084d17a70dead90a3531cab30#body_text
is schema:about of	named entity 'led' named entity 'drugs' named entity 'toxicity' named entity 'animal' named entity 'studies' named entity 'referred' named entity 'Clinical Trials' named entity 'human trials' named entity 'animal research' named entity 'Clinical Trials' named entity 'Preclinical Trials' named entity 'alternative methods' named entity 'clinical trials' named entity 'low-molecular-weight' named entity 'intracellular' named entity 'mice' named entity 'reproducibility' named entity 'Australia' named entity 'adverse side effects' named entity 'antihistamines' named entity 'autoimmune diseases' named entity 'lupus' named entity 'drug development' named entity 'pulmonary edema' named entity 'animal studies' named entity 'FDA-approved' named entity 'drug development' named entity 'Europe' named entity 'cardiac tissue' named entity 'off-label' named entity 'animal models' named entity 'Chloroquine' named entity 'heart cells' named entity 'drug approval' named entity 'heart muscle' named entity 'drug testing' named entity 'toxicity testing' named entity 'Animal research' named entity 'human clinical trials' named entity 'preclinical' named entity 'therapeutic agents' named entity 'hepatotoxicity' named entity 'toxicity' named entity 'guinea pigs' named entity 'computational simulations' named entity 'approved drugs' named entity 'infection' named entity 'preclinical' named entity 'clinical data' named entity 'diseases and conditions' named entity 'medical drugs' named entity 'Japan' named entity 'toxicity' named entity 'QT prolongation' named entity 'animal testing' named entity 'electrophysiologic' named entity 'side-effect' named entity 'analgesics' named entity 'New Zealand' named entity 'marginal likelihood' named entity 'clinical trials' named entity 'dog' named entity 'muscle' named entity 'therapeutic agents' named entity 'University of California, San Francisco' named entity 'marketing approval' named entity 'toxicity' named entity 'antibiotics' named entity 'pulmonary edema' named entity 'approved drug' named entity 'FDA' named entity 'FDA' named entity 'toxicity' named entity 'clinical testing' named entity 'calcium' named entity 'drug development' named entity 'cosmetic industry' named entity 'clinical trials' named entity 'toxicity' named entity 'malaria' named entity 'toxicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software